🚨 Last chance to register!
Join our webinar tomorrow on digital health navigators in prescription digital therapeutics.
📅 Mar 24 | ⏰ 3 PM ET
🔗 Secure your spot: landingpage.jmirpublications.com/bridging-inn...
#DigitalHealth #DigitalTherapeutics #DigitalPsychiatry #Webinar #LastChance

Locomotive Syndrome Digital Therapeutics Provided via a Smartphone App: Proof-of-Concept Single-Group Trial Study Background: Individuals with locomotive syndrome (LS) have muscle weakness and reduced motor function due to musculoskeletal disorders that cause reduced mobility and physical function. In Japan, musculoskeletal disorders are the most common reason for requiring home support or nursing care, highlighting the need for preventing and ameliorating LS. Middle-aged and older adults sometimes encounter difficulty making a habit of exercise therapy (the mainstay of LS treatment). Objective: We investigated whether digital therapeutics (DTx) can prevent or ameliorate LS in middle-aged and older adults. Methods: We conducted a prospective, longitudinal, nonrandomized, single-group study of Japanese aged 40 years and older who were eligible for LS checkups (N=47). Each participant underwent an 8-week locomotion training intervention based on DTx supervised by medical staff. We objectively assessed the participants’ subjective and objective motor abilities and motor awareness with the Timed Up and Go (TUG) test, 25-question Geriatric Locomotive Function Scale (GLFS-25), and Behavioral Regulation in Exercise Questionnaire-3 at baseline (before the DTx), an interim point (4 wk after the DTx initiation), and a final evaluation (8 wk post-DTx initiation). We compared the scores of the 3 tests at the 3 time points as dependent variables in a 3-factor ANOVA with Bonferroni correction (significance defined as 0.05/3=0.0167). Results: No increase in amotivation to exercise or refusal to exercise was observed. Significant improvements at 8 weeks versus the baseline were observed in the TUG scores (baseline: 9.0, 95% CI 8.4‐9.6; 8 wk: 7.5, 95% CI 7.1‐8.0; =.001) and GLFS-25 results (baseline: 18.7, 95% CI 14.5‐22.8; 8 wk: 11.7, 95% CI 8.8‐14.7; =.004). The Behavioral Regulation in Exercise Questionnaire-3 and its subscale data did not differ significantly at any assessment time point. Conclusions: These results indicate that an 8-week locomotive training intervention using DTx significantly improved middle-aged and older adults’ TUG and GLFS-25 scores and will help prevent and ameliorate LS and establish better exercise habits among them. Trial Registration: University Hospital Medical Information Network Clinical Trial Registry UMIN000053922;

New in JMIR Aging: Locomotive Syndrome Digital Therapeutics Provided via a Smartphone App: Proof-of-Concept Single-Group Trial Study #LocomotiveSyndrome #DigitalTherapeutics #ExerciseTherapy #MusculoskeletalHealth #MobileHealth

Wellmind Heath digital therapeutics innovation & impact newsletter graphic stating the content.

Our latest digital therapeutics innovation & impact newsletter is live, highlighting some key partnership projects that see Be Mindful, Pathway through Pain & Meditainment addressing:

▪️ Accessibility
▪️ Employment
▪️ Waiting lists
▪️ Addiction recovery

#digitaltherapeutics

tinyurl.com/3t93punj

Digital Neurotherapeutics Market Size, Growth, Report 2035 Digital Neurotherapeutics Market to grow at 16.80% CAGR, reaching USD 29.98 Billion by 2035, driving, size, growth, global trends, competitive analysis and industry outlook 2025-2035.

Software-driven therapies for neurological conditions boost the Digital Neurotherapeutics Market. 🧠📱 www.marketresearchfuture.com/reports/digi...
#DigitalTherapeutics

India Electronic Pill Market Size, Growth Outlook 2035 India Electronic Pill Market projected to grow at 7.512% CAGR, reaching USD 484.5 Million by 2035, driving growth global trends, competitive industry analysis and outlook 2025-2035.

💊 India’s Electronic Pill Market is emerging with smart medication adherence & digital health innovations. Discover growth potential. www.marketresearchfuture.com/reports/indi... #DigitalTherapeutics

Systematic Review and Thematic Analysis of Digital Games for Cognitive Enhancement in Children With Autism Spectrum Disorder: Toward a Conceptual Framework Games boosting autistic cognition? Review of 34 studies: Digital tools with incentives/motivation enhance skills—25 saw gains. Parent-therapist framework key, but trials needed. Level up ASD? #AutismResearch #DigitalTherapeutics

Games boosting autistic cognition? Review of 34 studies: Digital tools with incentives/motivation enhance skills—25 saw gains. Parent-therapist framework key, but trials needed. Level up ASD? #AutismResearch #DigitalTherapeutics
www.rimpacts.com/rd/p?c=10019... 📄DOI: doi.org/10.1007/s125...

#affectivecomputing #AIchatbotsmentalhealth #AIinPTSDtherapy #behavioralhealth #CBT #Chatbots #cliniciandecisionsupport #CPT #digitalphenotyping #digitaltherapeutics #EMDR #mentalhealthtechnology #mentalhealthwearables #NLPintherapy #Personalizedmedicine
miltonmarketing.com/?p=81817

The Rise of Virtual Reality Therapy and Training Beyond the Game: How Virtual Reality is Reshaping Therapy and Training Remember when video games were just… games? A fun escape, a way to slay dragons or race supercars from…

The Rise of Virtual Reality Therapy and Training #therapeuticVR #corporateVRtraining #softskillsVRtraining #surgicaltrainingsimulation #mentalhealthtechnology #digitaltherapeutics #immersivelearning #VRinhealthcare #PTSDtreatmentwithVR #VRtrainingsolutions

Hyfe bolsters clinical data for chronic cough digital therapeutic Hyfe’s AI-driven digital cough therapy reduced cough frequency by more than 40% in patients suffering from refractory and unexplained chronic cough.

Hyfe’s AI-powered Behavioral Cough Suppression Therapy reduced chronic cough frequency by over 40% and improved quality of life for 80% of participants.

#News #DigitalHealth #ClinicalResearch #AIHealthcare #ChronicCough #DigitalTherapeutics #HealthInnovation

Hyfe bolsters clinical data for chronic cough digital therapeutic Hyfe’s AI-driven digital cough therapy reduced cough frequency by more than 40% in patients suffering from refractory and unexplained chronic cough.

Hyfe’s AI-powered Behavioral Cough Suppression Therapy reduced chronic cough frequency by over 40% and improved quality of life for 80% of participants.

#News #DigitalHealth #ClinicalResearch #AIHealthcare #ChronicCough #DigitalTherapeutics #HealthInnovation

Assessing the #usability of a Prescription-Based Mobile App for Patients With Panic Disorder and Its Management Console for Clinicians: Controlled User Study Background: Panic disorder is characterized by sudden panic attacks and persistent anticipatory anxiety. While pharmacotherapy remains effective, patients with panic disorder often experience residual symptoms and functional impairments. Lifestyle factors influence symptom severity but are often unaddressed in routine psychiatric care. Most current digital therapeutics for panic disorder have limited scope, lack integration with clinicians, and fail to consider behavioral patterns. To address these limitations, our research team developed a prescription-based app that supports structured cognitive behavioral therapy practice, real-life symptom management, and lifestyle modifications for patients with panic disorder, and a management console, a web-based platform that allows clinicians to monitor the patients’ engagement and progress and determine therapeutic options if necessary. Objective: This study tested the #usability of the app and management console by evaluating their interface, functionality, and user experience. The primary goal was to identify the strengths and areas for further improvement of these software devices, and to develop a list of modifications to improve the user experience and clinical applicability in updates to refine the devices for a future clinical trial. Methods: #usability data was collected by investigators at a medical device #usability research center without the involvement of the development research team, and the participants were 15 patients with panic disorder and 15 psychiatrists. Each group completed experimental use of the app or management console and scoring the convenience and safety by its modules, questionnaire evaluations for the acceptability, and presentation of verbal subjective feedback on areas for improvement. Based on the participants’ suggestions, a list of items that need to be modified to improve functionality and ease of use for each device was created. Results: Patients completed 155 assigned tasks for the app with over 98% success, and psychiatrists completed 34 tasks for the management console with over 86% success. The convenience and safety scores for the app and management console exceeded the neutral threshold (all: mean > 4.5). For all statements about the acceptability, both patients and psychiatrists responded at the level of agreeing with a score exceeding 3 (mean: 3.6 ~ 4.3 and 4.0 ~ 4.7, respectively). There were 38 suggestions for app improvements and 66 suggestions for management console improvements, most of which were incorporated in the modification list. Conclusions: Patients reported that the app might be easy to use and help manage anxiety, and psychiatrists found the management console practical and well-suited for outpatients. By combining patient-facing therapeutic tools with clinician-driven prescription and monitoring, the devices offer a solution aligned with clinically integrated, real-world psychiatric care. Modified devices based on the improvement suggestions presented in this study will be evaluated in future clinical trials for their impact on engagement and treatment outcomes.

JMIR Formative Res: Assessing the #usability of a Prescription-Based Mobile App for Patients With Panic Disorder and Its Management Console for Clinicians: Controlled User Study #MentalHealth #PanicDisorder #DigitalTherapeutics #CognitiveBehavioralTherapy #MobileHealth

We’re all set to meet patients at the Community Appointment Day in Weston-super-Mare - helping people access their local #MSK support app and manage their recovery with confidence.

#Musculoskeletal #MSKCare #ClinicalTransformation #SelfManagement #DigitalTherapeutics

Digital Therapeutic Market Projected to Hit USD 45.69 Billion by 2032, at a Exceptional CAGR 21.55% Authenticated data presented in the Digital Therapeutics Market report is based on findings of extensive primary and secondary research.

💻 The Digital Therapeutics Market is projected to hit USD 45.69 Bn by 2032 with an exceptional 21.55% CAGR! 🔗 www.einpresswire.com/article/7765... #DigitalTherapeutics #HealthTech #DigitalHealth

HealthDay interviews Julie Carbray, PhD, Co-Director of Psych Congress 2025, and Christoph Correll, MD, about key congress topics including sleep, mental health, and schizophrenia treatment.
youtu.be/0QWhbZhBbQg

#MentalHealth #DepressionTreatment #ADHDTreatment #SleepHealth #DigitalTherapeutics

Digital Therapeutics: Closing the Gaps in Chronic Care Digital therapeutics will likely serve as a cornerstone of hybrid care models. In these setups, patients receive a combination of.....

In this insightful piece for HIT Consultant Media, Brillio’s Avantika Sharma explores the evolving landscape of Digital Therapeutics and how it promises to shape the future of chronic care delivery. (2/2)
hitconsultant.net/2025/09/09/d...

#DigitalTherapeutics #Healthcare

👉 Don’t miss the next #ESMOOnAir webinar! Explore tumour-treating fields, #digitaltherapeutics, #radioligand therapy & more.

🔗 buff.ly/SlBoQXl

Unlocking SaMD Insurance Strategies: From Therapy Apps to AI Diagnostics Discover the latest SaMD insurance strategies in our seminar led by experts in the field. Join us for practical insights and real-world examples.

Unlocking SaMD Insurance Strategies: From Therapy Apps to AI Diagnostics #Japan #healthcare #Tokyo #SaMD #DigitalTherapeutics

Encouraging General Practitioners to Refer Patients With Insomnia to a Digital Therapeutic (Sleepio): #feasibility Repeated-Measures Intervention Study Background: Sleepio, a digital therapeutic offering digital cognitive behavioural therapy for insomnia, has been recommended by the National Institute for Health and Care Excellence (NICE) in the United Kingdom as an alternative to offering sleep hygiene or sleeping pills. However, understanding of the referral behaviour of general practitioners (GPs) regarding Sleepio is lacking. Objective: The aim of this study was to investigate the #feasibility of using an intervention targeting GPs in Scotland to increase referrals of insomnia patients to Sleepio. Methods: GPs working in primary care in Scotland were invited to join the study. GPs were recruited through the Primary Care Research Network in Scotland from June 10, 2024 to October 13, 2024. The behaviour change wheel was used to inform the design of the intervention. During the intervention, GPs reviewed an orientation on using Sleepio and received a visual reminder midway through the intervention. The primary outcome was the number of Sleepio referrals every two weeks over two months. The secondary outcome was the change in the GPs’ reported confidence level that Sleepio will be successful in reducing patients’ insomnia symptoms, and confidence in recommending Sleepio to patients. Results: : Of the 23 GPs who joined the study, 16 completed all stages. 68.8% of participants were females, the mean age was 42 years (SD, 8 years). The total number of Sleepio referrals in two months was 96 for all 16 GPs. In the first two weeks of the intervention, the mean referral rate to Sleepio was 22.4% for all 16 GPs, but this rate increased to 45% by the end of week 8. A repeated measures analysis indicated there was no statistically significant difference in GPs referral rates across four data points. GPs reported confidence level in recommending Sleepio increased significantly (Z = -3.436, P < 0.01), from a mean of 5.44 (somewhat confident) to 8.13 (very confident). Conclusions: This study explored the #feasibility and impact of an intervention aimed at supporting GPs’ to refer patients with insomnia to the digital therapeutic, Sleepio. Improvements were seen in GP-reported confidence levels at recommending Sleepio. A large-scale intervention and a longer study duration could provide useful information concerning how long the intervention effect on GPs’ behaviour towards Sleepio referrals might be sustained.

JMIR Formative Res: Encouraging General Practitioners to Refer Patients With Insomnia to a Digital Therapeutic (Sleepio): #feasibility Repeated-Measures Intervention Study #Insomnia #Sleepio #DigitalTherapeutics #CBT #SleepHealth

We're pleased to announce that, following a contract signing with Camden MSK, our digital self-management support for those Living with Pain will soon be available to their patients alongside the #MSK pathways.

#MSKPain #PersistentPain #DigitalTherapeutics #MSKCare

Digital Therapeutics Market to Observe High Paced Progress from 2025 to 2035 - News and Updates Digital Therapeutics Market is expected to gain profitable growth during Forecast Period of 2025 to 2035, Digital Therapeutics Market is Categorized by Type, Diagnosis, Treatment, Application, and Reg...

Digital Therapeutics 📲💊
Apps that heal 💡 Digital therapeutics are merging tech + medicine for real health gains 🚀
#DigitalTherapeutics #HealthTech #MedInnovation

www.marketresearchfuture.com/press-releas...

Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app

#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD

🚨 Psychedelic therapy isn’t one-size-fits-all.

AI + Digital Therapeutics are making treatment personalized at scale:
⚡ Precision patient modeling
⚡ Wearables for real-time guidance
⚡ Adaptive integration tools

New deep dive in my series:
🔗 bit.ly/3HeoDHZ

#AI #Psychedelics #DigitalTherapeutics

Development of a Sham Smartphone App for Opioid Use Disorder: Acceptability and Suitability Study Background: Despite having evidence-based medication for opioid use disorder, dropout is one of the most common issues noted with this treatment, indicating that new strategies are needed to improve retention and engagement. Prescription digital therapeutics, which are app-based interventions prescribed by a healthcare professional, have the potential to increase adherence to medication for opioid use disorder and retention while overcoming treatment barriers, including provider capacity and patient access. Using a sham app as a control condition for a randomized clinical trial is an innovative method to establish true efficacy of these apps. Objective: This study included the development and testing of a sham smartphone app for opioid use disorder. Methods: After the sham app was developed, participants were enrolled in a 4-week trial examining the use and suitability of the sham app as a control condition. Criteria for determining suitability included (1) participants believe the sham app is an active intervention and (2) participants experience no clinical improvements in depression severity or quality of life after using the sham app. Self-reported depression severity and quality of life were captured before and after using the sham app. A user satisfaction survey and semi structured interviews were conducted at the end of the study. Quantitative analyses included paired two-tailed t-tests. The semi structured interviews were conducted with 20 of the 21 participants, and these interviews were analyzed using rapid qualitative analysis. Results: Overall, 21 participants (Mage=42.0 [SD=6.4], 9 [42.9%] female, and 12 [57.1%] male) were enrolled. Average number of app log ins was 17.8 (SD=10.6) with a range of 1 to 41. There were 2 participants who only logged in 1 time, and 15 (71.4%) participants completed the goal of logging in an average of 3 times per week. No significant differences were found in depression severity (p=.50) or quality of life (quality of life p=.42, physical health p=.58, psychological health p=.07, environmental health p=.44, social relationships p=.86) after using the sham app. Of the 20 participants who completed the semi-structured interview, 19 (95%) believed that they were using an active intervention. The user satisfaction survey revealed high overall satisfaction with the sham app with a score of 91%. Qualitative analyses revealed several recurring themes, including perceived value and impact, potential for behavior change, usage patterns and engagement, perspective and #usability, and perceptions of authenticity. Conclusions: Our sham app met our a priori criteria for suitability as a sham app. No clinical improvements from baseline were observed at end of the study period, and all but one participant believed that they were using an active intervention. Demonstrating that this sham app is suitable as a control condition elevates the rigor of randomized clinical trials and ensures the efficacy of prescription digital therapeutics.

JMIR Formative Res: Development of a Sham Smartphone App for Opioid Use Disorder: Acceptability and Suitability Study #OpioidUseDisorder #DigitalTherapeutics #HealthTech #MentalHealth #SmartphoneApps

More importantly, these are new engaged individuals actively using the app to prevent, manage, or treat their #MSK conditions alongside routine NHS care.

#DigitalHealth #DigitalTherapeutics #MSKCare #MusculoskeletalHealth #HealthAndWork #ClinicalTransformation

Would you be interested in reviewing the slides from my presentation? Comment "chronic cough DTx" and I’ll send them to you via DM.
#DigitalTherapeutics #DTx #DigitalHealth #ChronicCough

Pharmacy in the Digital Age - School of Pharmacy As health care goes digital, School of Pharmacy alumni at the forefront explore how wearables, AI, remote monitoring, and more are revolutionizing pharmacy.

#Pharmacy is going digital—and School of Pharmacy alumni Paria Sanaty Zadeh, Dalia Saleh & Megan Coder are leading the way, from AI to wearables.

“#Pharmacists are in a prime position to be the experts patients turn to,” says Coder. #DigitalTherapeutics pharmacy.wisc.edu/2025/03/25/p...

Neuroscience Weekly News – April 23rd 2025 Next-Level Neuroscience Innovations: Digital Migraine Therapy, EU Alzheimer’s Approval, AI in MS, Parkinson’s Breakthroughs & More!   🧠 In this […] The post Neuroscience Weekly News – April 23rd 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Neuroscience Weekly News – April 23rd 2025 #News #AlzheimersDisease #digitaltherapeutics Comment below!

Neuroscience Weekly News – April 23rd 2025 Next-Level Neuroscience Innovations: Digital Migraine Therapy, EU Alzheimer’s Approval, AI in MS, Parkinson’s Breakthroughs & More!   🧠 In this […] The post Neuroscience Weekly News – April 23rd 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Neuroscience Weekly News – April 23rd 2025 #News #AlzheimersDisease #digitaltherapeutics Comment below!

Neuroscience Weekly News – April 23rd 2025 Next-Level Neuroscience Innovations: Digital Migraine Therapy, EU Alzheimer’s Approval, AI in MS, Parkinson’s Breakthroughs & More!   🧠 In this […] The post Neuroscience Weekly News – April 23rd 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Neuroscience Weekly News – April 23rd 2025 #News #AlzheimersDisease #digitaltherapeutics Comment below!

FDA approves Click’s digital therapeutic for episodic migraine - PharmaTimes More than 37 million adults in the US are affected by migraine

#ClickTherapeutics #digitaltherapeutics #softwareenhanceddrugs #episodicmigraine #migraine #CT132 #preventionofepisodicmigraine #migraineprevention #migrainepatients #ReMMiDclincialtrial #migrainedays #ReMMiDCbridgingstudy #calcitoningenerelatedpeptideinhibitors
pharmatimes.com/news/fda-app...